Olema Highlights Encouraging OP-3136 Phase 1 Oncology Results

Detailed price information for Olema Pharmaceuticals Inc (OLMA-Q) from The Globe and Mail including charting and trades.
Nasdaq

Guggenheim Initiates Coverage of Olema Pharmaceuticals (OLMA) with Buy Recommendation

As of September 30, 2025, the average one-year price target for Olema Pharmaceuticals is $24.82/share. The forecasts range from a low of $18.18 to a high of $31.50. The average price target represents ...
NJ.com

No. 3 OLMA starts fast, cruises past No. 4 Trinity Hall in Non-Public South final

Right from the opening event, it was clear that Our Lady of Mercy was determined to avenge last year’s defeat. After the quartet of Simone McGlinchey, Scarlett McGlinchey, Gianna Cook, and Gia ...
Insider Monkey

H.C. Wainwright Backs Olema Pharmaceuticals (OLMA) as Phase 3 Trials Advance

H.C. Wainwright reiterated its Buy rating and $28 price target for Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) on May 29, following an update on the company continuing clinical trials. On May 28, Olema ...

Olema: The Market Overreacted To Roche's SERD Failure

Olema Pharmaceuticals awaits Phase 3 breast cancer data in fall 2026, with $505M in cash to fund catalysts. Learn why OLMA ...
Nasdaq

OLMA Stock Soars 47% in September So Far on Second PFE Deal

Shares of Olema Pharmaceuticals OLMA have rallied 46.5% so far in September after the company announced a new collaboration agreement for its lead product candidate, palazestrant, with pharma bigwig ...